GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma

Abstract

Our experimental data indicate the potential efficacy of CAR.GD2 T-cell therapy. A phase I/II clinical trial is ongoing in our center (NCT05298995) to evaluate the safety and therapeutic efficacy of CAR.GD2 therapy in high-risk MB patients.